Convergence Pharmaceuticals has reported positive data from a Phase II trial of novel sodium channel blocker CNV1014802 in patients with trigeminal neuralgia (TGN), a very severe form of facial pain.
written on 16.06.2014
GSK spin-out Convergence considers all options after positive face pain data
